title: Contingency management reduces drug-related human immunodeficiency virus risk behaviors in cocaine-abusing methadone patients.
abstract: OBJECTIVE
  Contingency management (CM) is efficacious in reducing drug use. This study examined whether CM also reduces human immunodeficiency virus (HIV) risk behaviors and if these effects are mediated by longest duration of abstinence achieved during treatment.
  
  
  METHODS
  Data were analyzed from a subset of participants in a combined data set of three published randomized controlled trials of CM treatments.
  
  
  METHODS
  A community-based methadone maintenance clinic.
  
  
  METHODS
  One-hundred and sixty-five cocaine-abusing methadone maintenance patients.
  
  
  METHODS
  Participants received either standard methadone treatment or standard methadone treatment with CM for 3 months.
  
  
  METHODS
  The HIV Risk Behavior Scale (HRBS) was administered prior to randomization to a study condition and 3 months after the study treatments ended. The primary objective indicator of drug use was longest duration of cocaine and opioid abstinence achieved during treatment.
  
  
  RESULTS
  Relative to those assigned to standard care, participants receiving CM significantly decreased overall HIV risk behaviors and injection drug use risk behaviors. CM participants also achieved longer durations of consecutive cocaine and opioid abstinence during treatment. Duration of abstinence achieved mediated the relationship between treatment condition and HRBS difference scores.
  
  
  CONCLUSIONS
  These results suggest that CM treatment reduces HIV drug use risk behaviors in cocaine-abusing methadone maintenance patients.
authors.affiliation: University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT 06030-3944, USA.
authors.forename: Tressa
authors.initials: T
authors.lastname: Hanson
authors.forename: Sheila M
authors.initials: SM
authors.lastname: Alessi
authors.forename: Nancy M
authors.initials: NM
authors.lastname: Petry
mesh_terms: D000328:Adult; D000701:Analgesics, Opioid / Q000627:therapeutic use*; D001521:Behavior Therapy / Q000379:methods*; D005260:Female; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D006801:Humans; D008297:Male; D008691:Methadone / Q000627:therapeutic use*; D016485:Needle Sharing / Q000009:adverse effects; D009293:Opioid-Related Disorders / Q000150:complications* / Q000534:rehabilitation; D012309:Risk-Taking; D012725:Sexual Behavior / Q000523:psychology*; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D008691:Methadone